Ben Chien, Chairman, President and CEO, of Foresee Pharmaceuticals, one of Taiwan’s most vibrant success stories, discusses how Foresee has achieved successful phase III results for its prostate cancer treatment, FP-001, IPOed and entered into a partnership agreement with Ferring in the last year alone. In addition, he discloses how the company plans to leverage its MMP12 technology platform to ensure future growth.
You have achieved impressive things in both science and business; after successfully founding QPS Holdings, Inc. and Theracore Pharmaceuticals, what motivated you to establish Foresee Pharma?
"After 21 years of serving the industry, the backbone that really drove us to establish Foresee was purely based on science."
